Equities

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co Ltd

Actions
  • Price (EUR)10.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+21.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Santen Pharmaceutical Co Ltd grew revenues 8.22% from 279.04bn to 301.97bn while net income improved from a loss of 14.95bn to a gain of 26.64bn.
Gross margin57.92%
Net profit margin8.64%
Operating margin12.33%
Return on assets6.25%
Return on equity8.76%
Return on investment7.77%
More ▼

Cash flow in JPYView more

In 2024, Santen Pharmaceutical Co Ltd increased its cash reserves by 63.35%, or 36.68bn. The company earned 72.65bn from its operations for a Cash Flow Margin of 24.06%. In addition the company used 6.15bn on investing activities and also paid 34.03bn in financing cash flows.
Cash flow per share124.22
Price/Cash flow per share13.64
Book value per share827.65
Tangible book value per share600.21
More ▼

Balance sheet in JPYView more

Santen Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 16.39%, a higher figure than the previous year's 11.04%.
Current ratio2.61
Quick ratio1.97
Total debt/total equity0.1955
Total debt/total capital0.1639
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.09%
Div growth rate (5 year)4.88%
Payout ratio (TTM)46.36%
EPS growth(5 years)-1.60
EPS (TTM) vs
TTM 1 year ago
3.79
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.